<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<References xsi:schemaLocation="http://www.iedb.org/schema/CurationSchema http://beta.iedb.org/schema/Curation.xsd" xmlns="http://www.iedb.org/schema/CurationSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <Reference>
        <ReferenceId>951</ReferenceId>
        <DateLastUpdated>2020-09-10-07:00</DateLastUpdated>
        <Article>
            <PubmedId>1700833</PubmedId>
            <Abstract>To define the recognition site of cytotoxic T lymphocytes (CTLs) on influenza virus H5 hemagglutinin (HA), an H5 HA-specific CTL clone was examined for the ability to recognize monoclonal antibody-selected HA variants of influenza virus A/Turkey/Ontario/7732/66 (H5N9). On the basis of 51Cr release assays with the variants, a CTL epitope was located near residue 168 of H5 HA. To define the epitope more precisely, a series of overlapping peptides corresponding to this region was synthesized and tested for CTL recognition. The minimum peptide recognized by the CTL clone encompassed residues 158 to 169 of H5 HA. Relative to the H3 HA three-dimensional structure, this CTL epitope is located near the distal tip of the HA molecule, also known as a major B-cell epitope on H3 HA. A single mutation at residue 168 (Lys to Glu) in the H5 HA variants abolished CTL recognition; this same amino acid was shown previously to be critical for B-cell recognition (M. Philpott, C. Hioe, M. Sheerar, and V. S. Hinshaw, J. Virol. 64:2941-2947, 1990). Additionally, mutations within this region of the HA molecule were associated with attenuation of the highly virulent A/Turkey/Ontario/7732/66 (H5N9) (M. Philpott, B. C. Easterday, and V.S. Hinshaw, J. Virol. 63:3453-3458, 1989). When tested for recognition of other H5 viruses, the CTL clone recognized the HA of A/Turkey/Ireland/1378/83 (H5N8) but not that of A/Chicken/Pennsylvania/1370/83 (H5N2), even though these viruses contain identical HA amino acid 158-to-169 sequences. These results suggest that differences outside the CTL epitope affected CTL recognition of the intact HA molecule. The H5 HA site defined in these studies is, therefore, important in both CTL and B-cell recognition, as well as the pathogenesis of the virus.</Abstract>
            <ArticleYear>1990</ArticleYear>
            <ArticlePages>6246-51</ArticlePages>
            <ArticleTitle>Overlapping cytotoxic T-lymphocyte and B-cell antigenic sites on the influenza virus H5 hemagglutinin.</ArticleTitle>
            <Authors>
                <Author>
                    <LastName>Hioe</LastName>
                    <ForeName>C E</ForeName>
                </Author>
                <Author>
                    <LastName>Dybdahl-Sissoko</LastName>
                    <ForeName>N</ForeName>
                </Author>
                <Author>
                    <LastName>Philpott</LastName>
                    <ForeName>M</ForeName>
                </Author>
                <Author>
                    <LastName>Hinshaw</LastName>
                    <ForeName>V S</ForeName>
                </Author>
            </Authors>
            <Affiliations>Department of Pathobiological Sciences, University of Wisconsin-Madison 53706.</Affiliations>
            <ArticleChemicalList>Epitopes;Hemagglutinin Glycoproteins, Influenza Virus;Hemagglutinins, Viral</ArticleChemicalList>
            <ArticleMeshHeadingsList>Amino Acid Sequence; Animals; B-Lymphocytes(immunology); Cell Line; Chickens; Cytotoxicity, Immunologic; Epitopes(immunology); Female; Genetic Variation; Hemagglutinin Glycoproteins, Influenza Virus; Hemagglutinins, Viral(genetics; immunology); Influenza A virus(genetics; immunology); Mice; Mice, Inbred BALB C; Models, Molecular; Molecular Sequence Data; Mutagenesis, Site-Directed; Protein Conformation; T-Lymphocytes, Cytotoxic(immunology); Turkeys</ArticleMeshHeadingsList>
            <Journal>
                <Volume>64</Volume>
                <Issue>12</Issue>
                <Title>Journal of virology</Title>
                <Issn>1098-5514</Issn>
                <MedlineTa>J Virol</MedlineTa>
            </Journal>
        </Article>
        <Epitopes>
            <Epitope>
                <EpitopeName>HA 158-169</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>SFYRNVVWLIKK</LinearSequence>
                        <StartingPosition>158</StartingPosition>
                        <EndingPosition>169</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>P16060.2</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>380301</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Table 2</LocationOfData>
                <EpitopeId>57960</EpitopeId>
                <ReferenceStartingPosition>158</ReferenceStartingPosition>
                <ReferenceEndingPosition>169</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>This epitope represents the minimal epitope that was deduced from overlapping peptide studies.  It was subsequently synthesized and assayed.</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Text</LocationOfData>
                        <TCellId>11574</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <DiseaseState>ONTIE:0003423</DiseaseState>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>380301</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Influenza A virus (A/turkey/Ontario/7732/66(H5N9))</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <InVitroAdministration>
                                <ProcessType>Restimulation in vitro</ProcessType>
                                <ResponderCellType>Splenocyte</ResponderCellType>
                                <StimulatorCellType>Splenocyte</StimulatorCellType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>380301</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </InVitroAdministration>
                            <ImmunizationComments>The CTL clone was isolated by limiting dilution from a Ty/Ont-specific CTL line and then passaged weekly with A/Turkey/California/Hurst-2/71 (H5N2)-infected,irradiated, syngeneic spleen cells with a concanavalinA-stimulated rat splenocyte culture supernatant as asource of T-cell growth factors.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellType>T cell</CellType>
                            <CellCultureConditions>Cell Line / Clone</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Lymphoid</CellTissueType>
                            <CellType>B cell</CellType>
                            <CellCultureConditions>Cell Line / Clone</CellCultureConditions>
                            <AutologousOrSyngeneic>N</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>169</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>HA 158-169</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>SFYRNVVWLIKK</LinearSequence>
                                        <StartingPosition>158</StartingPosition>
                                        <EndingPosition>169</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P16060.2</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>380301</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>67</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>The Lysine residue at position 168 was also shown to be a critical resudue for epitope recognition in mutation assays.  The epitope-specific CTL clone was cross-reactive to H5 hemagglutinin of the Ty/Ont/7732/66 (H5N9), Ty/Ire/1378/83 (H5N8), and Ty/Ire/1378/83 (H5Vac)b influenza strains, which exhibit a high level of conservation at positions 158-169.  Cross reactivity was not observed to Ck/Scot/1/57 (H5N1) and Ck/Penn/1370/83 (H5N2) strains, which exhibit sequence conservation, suggesting that specific residues outside the CTL epitope may affect epitope processing or presentation.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
        </Epitopes>
    </Reference>
</References>

